DAX23.997 +0,3%ESt505.367 -0,1%Top 10 Crypto14,19 -0,4%Dow42.270 +0,1%Nas19.114 -0,3%Bitcoin91.844 -1,0%Euro1,1349 ±0,0%Öl63,90 -0,4%Gold3.292 ±0,0%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 Rheinmetall 703000 RENK RENK73 Lufthansa 823212 HENSOLDT HAG000 BYD A0M4W9 Tesla A1CX3T Siemens Energy ENER6Y Mercedes-Benz Group (ex Daimler) 710000 thyssenkrupp 750000 Deutsche Telekom 555750 Infineon 623100 D-Wave Quantum A3DSV9 Amazon 906866 Apple 865985
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
US-Börsen schließen uneins -- DAX geht knapp unter 24.000er-Marke ins Wochenende -- VW in Gesprächen mit US-Regierung über Zölle -- Marvell Technology, D-Wave, Rheinmetall, Bitcoin im Fokus
Top News
Neuzugang in den Top 3: So hat David Einhorns Greenlight Capital im ersten Quartal 2025 investiert Neuzugang in den Top 3: So hat David Einhorns Greenlight Capital im ersten Quartal 2025 investiert
Rheinmetall-Aktie steigt: So bewertet Deutsche Bank AG die Rheinmetall-Aktie Rheinmetall-Aktie steigt: So bewertet Deutsche Bank AG die Rheinmetall-Aktie
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
25 € Neukunden­bonus + 1 Aktie gratis. Hol Dir jetzt Dein finanzen.net ZERO-Depot!

Actinium Pharmaceuticals Aktie

Handeln
Aktien-Sparplan anlegen
1,36 EUR -0,04 EUR -3,13 %
FSE
1,54 USD -0,03 USD -1,91 %
nachbörslich
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.43,48 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA2QA48

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS00507W2061

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolATNM

Actinium Pharmaceuticals Aktien News

DatumMeistgelesen
PR NewswireActinium Highlights Mutation Data from the Phase 3 SIERRA Trial of Iomab-B and Novel Linker Technology to Support Solid Tumor Antibody Radiation Conjugate Development at the 2024 Society of Nuclea...
PR NewswireActinium to Host KOL Webinar to Discuss Iomab-ACT Commercial CAR T-Cell Therapy Trial Design, Objectives and Potential Market Opportunity
PR NewswireActinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients at the EHA 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients...
PR NewswireActinium Announces Multiple Abstracts Highlighting its Antibody Radiation Conjugates Iomab-B and Actimab-A and Novel Linker Technology for Solid Tumors Accepted for Presentation at the 2024 Societ...
PR NewswireActinium Announces KOL Webinar to Highlight Recently Announced Iomab-ACT Trial with Leading FDA Approved Commercial CAR T-Cell Therapy Being Led by the University of Texas Southwestern
PR NewswireActinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European ...
PR NewswireActinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Pre...
PR NewswireActinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy
PR NewswireActinium Pharmaceuticals Launches Actinium-225 Focused Strategic Initiative to Leverage Proprietary Cyclotron Based Manufacturing Technology to Address Growing Market Demand
PR NewswireActinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem Meetings | Tran...
PR NewswireActinium Highlights Improved Survival with Iomab-B in TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients in the SIERRA Trial and Other Presentations at the 2024 Tandem Meetings | Tr...
PR NewswireActinium Announces Acceptance of Five Abstracts for Presentation at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®
PR NewswireActinium Announces Iomab-B Produces High Response Rates and Significant Improvement in Overall Survival in Relapsed Refractory AML Patients with Active Disease Overcoming TP53 Mutation
PR NewswireActinium's Four Presentations at ASH Highlight the Positive Outcomes for Iomab-B and Actimab-A in Patients with Relapsed or Refractory Acute Myeloid Leukemia
PR NewswireActinium to Highlight Broad Potential of Targeted Radiotherapies Iomab-B and Actimab-A for Relapsed or Refractory and Elderly Acute Myeloid Leukemia Patients at the 65th ASH Annual Meeting & Expos...
PR NewswireActinium Presents Preclinical Data at SITC Demonstrating Actimab-A's Potential to Restore T Cell Immunity in the Solid Tumor Microenvironment Supporting Immunotherapy Combinations
PR NewswireActinium Pharmaceuticals to Attend Bio-Europe Munich 2023
PR NewswireActinium Announces Oral Presentation at ASH Annual Meeting Highlighting Iomab-B Treatment Significantly Increased Median Overall Survival in Relapsed or Refractory AML Patients with Highly Unfavor...
PR NewswireActinium Announces NIH Grant Extension to Advance Clinical Development of Next-Generation CD45 Targeted Conditioning Agent Iomab-ACT with Memorial Sloan Kettering's CAR-T Cell Therapy
PR NewswireActinium Pharma Highlights Abstract Accepted for Poster Presentation at the SITC 38th Annual Meeting
PR NewswireActinium Pharma Presents Survival Data from Extended Follow-Up from Actimab-A + CLAG-M Trial and Preclinical Data Supporting Program Expansion with FLT3 Inhibitor Combinations at SOHO
PR NewswireActinium Pharma Highlights Three Abstracts Accepted for Poster Presentation at the SOHO 2023 Annual Meeting
PR NewswireActinium Pharma Highlights Abstracts Accepted for Oral and Poster Presentation at the EANM 2023 Congress
PR NewswireActinium Pharma to Present at the 2nd Annual Targeted Radiopharmaceuticals Summit
PR NewswireSNMMI 2023 Annual Meeting Abstract of the Year Awarded to Actinium's Iomab-B Phase 3 SIERRA Data
PR NewswireActinium Pharma Highlights Six Abstracts Accepted for Oral and Poster Presentation at the SNMMI 2023 Annual Meeting
PR NewswireActinium Pharma to Present at the Maxim Healthcare Virtual Conference
PR NewswireActinium Pharma to Present at the TD Cowen Radiopharmaceutical Innovation Summit
PR NewswireActinium Announces Positive Pivotal Phase 3 SIERRA Trial Results in an Oral Presentation at the EHA 2023 Congress
PR NewswireActinium Pharma Set to Join Russell 2000® and Russell 3000® Indexes
PR NewswireActinium Pharma Announces Six Abstracts Accepted for Oral and Poster Presentation at the SNMMI 2023 Annual Meeting, Demonstrating Actinium's Leadership in Targeted Radiotherapy for Hematologic and...
PR NewswireActinium Pharma Announces Iomab-B SIERRA Trial Results Accepted for Oral Presentation at the European Hematology Association 2023 Congress (EHA)
PR NewswireActinium Pharma to Present at Guggenheim Healthcare Talks Radiopharmaceuticals Day
PR NewswireActinium Highlights Successful Administration of Targeted Radiotherapy Iomab-B Across Various BMT Centers with Ease and Without Increasing Radiation Exposure Risks to Treating Nursing Staff in the...
PR NewswireActinium Announces Positive Pivotal Phase 3 SIERRA Trial Results of Iomab-B Showcased to the European Transplant Community in Oral Presentation at the European Society for Blood and Marrow Transpl...
PR NewswireActinium Highlights First-In-Class HER3 Targeted Radiotherapy Data Demonstrating Potent Anti-Cancer Activity of in Ovarian and Colorectal Cancer Models at the AACR Annual Meeting
PR NewswireActinium Presents Data Demonstrating Actimab-A's Potential Use Against Solid Tumors by Selectively Depleting Immunosuppressive MDSCs, a Key Component of the Tumor Microenvironment, at the AACR Ann...
PR NewswireActinium Pharmaceuticals Reports 2022 Financial Results and Highlights Recent and Upcoming Clinical Data and Milestones
PR NewswireActinium to Showcase First-In-Class Targeted Radiotherapies in Two Presentations at the 2023 AACR Annual Meeting
PR NewswireActinium Pharmaceuticals, Inc. to Present at Oppenheimer's 33rd Annual Healthcare Conference
Wer­bung

Actinium Pharmaceuticals News

Actinium Pharmaceuticals News: auf dieser Seite finden Sie alle Actinium Pharmaceuticals News und Nachrichten zur Actinium Pharmaceuticals Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Actinium Pharmaceuticals News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Actinium Pharmaceuticals News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.